The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE)
Study Details
Study Description
Brief Summary
Background:
People with systemic lupus erythematosus (SLE) are at risk of developing complications in their blood vessels. This can increase the risk of heart attacks or stroke. No medications have been effective at reducing this risk in people with lupus.
Objective:
To test whether a drug (anifrolumab) can improve blood vessel function and reduce blood vessel inflammation in people with SLE.
Eligibility:
People aged 18 to 80 years with SLE.
Design:
Participants will undergo screening. They will have a physical exam. They will have blood and urine tests. They will have a test of their heart function and a chest X-ray. They will answer questions about their SLE symptoms.
Participants will visit the clinic 9 times in 8 months. After screening, visits will be 4 weeks apart. Each visit may take up to 4 hours.
Participants will receive infusions from a tube attached to a needle inserted into a vein in the arm (IV). Some will receive anifrolumab. Others will receive a placebo treatment. They will not know which one they are getting.
At some visits they will have additional tests:
CAVI (cardio-ankle vascular index) tests blood vessel function. Participants will lie still for 20 minutes. Small electrodes will be placed on both wrists with stickers. A microphone will be placed on their chest. Blood pressure cuffs will be wrapped around their ankles and arms.
FDG-PET/CT is an imaging procedure. Participants will receive a substance through an IV line. They will lie on a table for 110 minutes while a machine captures images of their body.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
Study Description:
This is a double blind placebo-controlled study to characterize whether blocking type I IFN receptor signaling with anifrolumab will lead to improvements in vascular function, decreases in vascular inflammation and modulation of biomarkers of vascular risk in patients with systemic lupus erythematosus (SLE).
Objectives:
Primary Objective: To assess the role of anifrolumab in modulating vascular function and vascular inflammation in SLE patients with mild to moderate disease activity as determined by Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) 2K<= 6.
Secondary Objectives: To assess the role of anifrolumab in modulating biomarkers of cardiovascular risk in SLE patients with mild to moderate disease activity as determined by SLEDAI 2K<= 6. Assess safety and tolerability of short-term use of anifrolumab
Endpoints:
Primary Endpoint(s):
-
Change from Baseline (Week 0) to Week 28 in cardio-ankle vascular index (CAVI).
-
Change from Baseline to Week 28 in pulse wave velocity (PWV) using Sphygmocor.
-
Change from Baseline to Week 28 in vascular inflammation as measured by target to background ratio (TBR) in various aortic territories and total aorta using FDG PET CT scans.
Secondary Endpoints:
Changes over time in biomarkers of cardiovascular risk/immune dysregulation and metabolic dysfunction previously described in SLE. These biomarkers include but not limited to lipoprotein profiles and high-density lipoprotein cholesterol efflux capacity, immune cell types, endothelial progenitor cells, circulating neutrophil extracellular traps, serum cytokines, acute phase reactants, insulin resistance, transcriptomic analysis of peripheral immune cells.
Tertiary: Safety, as assessed by severity and incidence of advese events and the change over time from baseline in laboratory variables.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Patient anifrolumab |
Drug: anifrolumab
This is a double blind placebo-controlled study to characterize whether blocking type I IFN receptor signaling with anifrolumab will lead to improvements in vascular function, decreases in vascular inflammation and modulation of biomarkers of vascular risk in patients with SLE.
|
| Placebo Comparator: Patient placebo placebo |
Other: Placebo
non-active substance comprised of 25 mM histidine/histidine-HCl, 50 mM lysine-HCl, 130 mM trehalose, and 0.05% (w/v) polysorbate 80, with a pH of 5.9.
|
Outcome Measures
Primary Outcome Measures
- role of anifrolumab [8 months]
1.Change from Baseline (Week 0) to Week 24 in cardio-ankle vascular index (CAVI). 2. Change from Baseline to Week 24 in pulse wave velocity (PWV) using Sphygmocor. 3. Change from Baseline to Week 24 in vascular inflammation as measured by target to background ratio (TBR) in various aortic territories and total aorta using FDG PET CT scans.
Secondary Outcome Measures
- Role of anifrolumab [8 months]
in modulating biomarkers of cardiovascular risk in SLE patients with mild to moderate disease activity as determined by SLEDAI 2K= 6. Assess safety and tolerability of short-term use of anifrolumab
Eligibility Criteria
Criteria
- INCLUSION CRITERIA:
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
-
Provision of signed and dated informed consent form
-
Stated willingness to comply with all study procedures and availability for the duration of the study
-
Male or female, aged 18-80 years
-
In good general health as evidenced by medical history or diagnosed with SLE diagnosed per American College of Rheumatology 1997 revised SLE classification criteria.
-
Prednisone < or equal to 10 mg/day for at least 2 weeks before screening and maintained throughout randomization (day 1)
-
Stable standard of care lupus therapies for at least 4 weeks before screening and maintained through randomization (day 1)
-
Abnormal cardio-ankle vascular index at screening (based on 2 SD above median of healthy controls based on historical data from our own patient cohorts)
-
Stable medications for diabetes, hypertension and/or statins for at least the previous 3 months. No changes of these medications or immunosuppressive drugs will be allowed during trial.
-
For females of reproductive potential: use of highly effective contraception from screening and agreement to use such a method during study participation and for an additional 8 weeks after the end of study medication administration
-
For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner
EXCLUSION CRITERIA:
An individual who meets any of the following criteria will be excluded from participation in this study:
-
Any condition that, in the opinion of the Investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results
-
Concurrent enrolment in another clinical study with an investigational product
-
Major surgery within 8 weeks before signing the ICF or elective major surgery planned during the study period
-
At Screening (within 4 weeks before Week 0 [Day 1]), any of the following: (a) Aspartate aminotransferase (AST) >2.5 X upper limit of normal (ULN). (b) Alanine aminotransferase (ALT) >2.0 X ULN. (c) Total bilirubin >ULN (unless due to Gilbert's syndrome) (d) Serum creatinine >2.5 mg/dL (or >181 micromol/L) (e) Urine protein/creatinine ratio >2.0 mg/mg (or >226.30 mg/mmol) (f) Neutrophil count <1000/microL (or <1.0 X 109/L) (g) Platelet count <25000/microL (or <25 X 109/L) (h) Hemoglobin <8 g/dL (or <80 g/L), or <7 g/dL (or <70 g/L) if related to subject's SLE such as in active hemolytic anemia (i) Glycosylated hemoglobin (HbA1c) >8% (or >0.08) at screening (diabetic subjects only)
Note: Abnormal screening laboratory tests may be repeated within 4 weeks ONCE on a separate sample before subject is declared a screen failure.
-
Receipt of any of the following: (a) Azathioprine >200 mg/day (b) Mycophenolate mofetil > 3 g/day or mycophenolic acid >2.16 g/day (c) Oral, SC, or intramuscular methotrexate >25 mg/week (d) Mizoribine >150 mg/day.
-
Receipt of any investigational product (small molecule or biologic agent) within 4 weeks or 5 half-lives prior to week 0 (day 1), whichever is greater.
-
Prior receipt of anifrolumab
-
Receipt of any commercially available biologic agent within 5 half-lives prior to signing of the ICF
-
Receipt of B cell-depleting therapy (including but not limited to, ocrelizumab, ofatumumab, atacicept, obinutuzumab, or rituximab) <26 weeks prior to signing the ICF; <40 weeks for atacicept or if therapy was administered greater than or equal to 26 weeks ago (40 weeks for atacicept), absolute B cell less than the lower limit of normal or baseline value prior to receipt of B cell-depleting therapy (whichever is lower)
-
Receipt of any of the following: (a) Intra-articular, intramuscular or IV corticosteroids within 4 weeks prior to Day 1 (b) Any live or attenuated vaccine within 8 weeks prior to signing the ICF (administration of killed vaccines is acceptable)
-
Medications that lead to immediate discontinuation of investigational product (a) Cyclophosphamide (b) IFN therapy (alpha 2a and 2b, beta 1a and 1b, and pegylated IFNs alpha 2a and 2b) (c) Investigational agents (d) Biologic immunomodulators (including, but not limited to, belimumab, abatacept, or rituximab) (e) Live or attenuated vaccines (f) Plasmapheresis (g) BCG vaccine (h) Any immunoglobulin (Ig) therapy (i) Intravenous corticosteroids >1 gm methylprednisolone or equivalent
-
History or evidence of suicidal ideation within the past 6 months; or any suicidal behavior within the past 12 months based on screening or at baseline
-
Recent cardiac or stroke event (with in the last year prior to week 0 (day 1))
-
Active SLE disease with SLEDAI 2K >6
-
Active severe or unstable neuropsychiatric SLE including, but not limited to: aseptic meningitis; cerebral vasculitis; myelopathy; demyelination syndromes (ascending, transverse, acute inflammatory demyelinating polyradiculopathy); acute confusional state; impaired level of consciousness; psychosis; acute stroke or stroke syndrome; cranial neuropathy; status epilepticus; cerebellar ataxia; and mononeuritis multiplex: (a) That would make the subject unable to fully understand the ICF OR (b) Where, in the opinion of the Principal Investigator (PI), protocol specified SOC is insufficient and utilization of a more aggressive therapeutic approach, such as adding IV cyclophosphamide and/or high dose IV pulse corticosteroid therapy or other treatments not permitted in the protocol, is indicated
-
Active severe SLE-driven renal disease where, in the opinion of the PI, protocol specified standard of care (SOC) is insufficient and utilization of a more aggressive therapeutic approach, such as adding IV cyclophosphamide and/or high dose IV pulse corticosteroid therapy or other treatments not permitted in the protocol, is indicated.
-
History of or current diagnosis of catastrophic or severe anti-phospholipid syndrome within 1 year prior to signing the ICF. Antiphospholipid syndrome adequately controlled by anticoagulant therapy for at least 3 months is acceptable.
-
Known history of a primary immunodeficiency, splenectomy, or any underlying condition that predisposes the subject to infection, or a positive result for human immunodeficiency virus (HIV) infection confirmed by central laboratory at screening. Subjects refusing HIV testing during the screening period will not be eligible for study participation
-
Confirmed positive test for hepatitis B serology for: (a) Hepatitis B surface antigen (HBsAg), OR (b) Hepatitis B core antibody (HBcAb) AND hepatitis B virus (HBV) DNA detected above the lower limit of quantitation (LLOQ) by reflex testing by the central laboratory at screening Note: Subjects who are HBcAb positive at screening will be tested every 3 months for HBV DNA. To remain eligible for the study, the subject s HBV DNA levels must remain below the LLOQ as per the central laboratory.
-
Positive test for hepatitis C antibody along with detectable Hepatitis C viral RNA.
-
Any severe herpes infection at any time prior to Week 0 (Day 1), including, but not limited to, disseminated herpes (ever), herpes encephalitis (ever), recurrent herpes zoster (defined as 2 episodes within 2 years) or ophthalmic herpes (ever)
-
Any herpes zoster, cytomegalovirus (CMV) or Epstein-Barr virus infection that has not completely resolved within 12 weeks prior to signing the ICF
-
Any of the following: (a) Clinically significant chronic infection (ie, osteomyelitis, bronchiectasis, etc) within 8 weeks prior to week 0 (day1) (chronic nail infections are allowed) (b) Any infection requiring hospitalization or treatment with IV antibiotics not completed at least 4 weeks prior to week 0 (day1)
-
Any infection requiring oral antimicrobials (including antivirals) within 2 weeks prior to Day 1, except if taking antivirals/antimicrobials prophylactically
-
History of cancer, apart from: (a) Squamous or basal cell carcinoma of the skin treated with documented success of curative therapy greater than or equal to 3 months prior to Week 0 (Day 1) (b) Cervical cancer in situ treated with apparent success with curative therapy greater than or equal to 1 year prior to Week 0 (Day 1).
-
Pregnancy or lactation or intend to become pregnant anytime from initiation of Screening until completion of study.
-
Spontaneous or induced abortion, still or live birth, or pregnancy less than or equal to 4 weeks prior to week 0 (day1)
-
Known allergic reactions to any component of the investigational product formulation or history of anaphylaxis to any human gamma globulin therapy
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | National Institutes of Health Clinical Center | Bethesda | Maryland | United States | 20892 |
Sponsors and Collaborators
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Investigators
- Principal Investigator: Mariana J Kaplan, M.D., National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 10000682
- 000682-AR